BIOCRYST PHARMACEUTICALS ($BCRX) is expected to release its quarterly earnings data on Monday, August 4th before market open, per Finnhub. Analysts are expecting revenue of $152,731,434 and earnings of $0.01 per share.
You can see Quiver Quantitative's $BCRX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BIOCRYST PHARMACEUTICALS Hedge Fund Activity
We have seen 140 institutional investors add shares of BIOCRYST PHARMACEUTICALS stock to their portfolio, and 102 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ASSENAGON ASSET MANAGEMENT S.A. added 3,606,566 shares (+25631.2%) to their portfolio in Q2 2025, for an estimated $32,314,831
- AVORO CAPITAL ADVISORS LLC removed 3,165,000 shares (-26.7%) from their portfolio in Q1 2025, for an estimated $23,737,500
- MILLENNIUM MANAGEMENT LLC added 3,022,769 shares (+382.6%) to their portfolio in Q1 2025, for an estimated $22,670,767
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) removed 2,954,777 shares (-36.3%) from their portfolio in Q1 2025, for an estimated $22,160,827
- ROCK SPRINGS CAPITAL MANAGEMENT LP removed 2,455,985 shares (-91.7%) from their portfolio in Q1 2025, for an estimated $18,419,887
- UBS GROUP AG added 2,162,834 shares (+899.9%) to their portfolio in Q1 2025, for an estimated $16,221,255
- D. E. SHAW & CO., INC. added 1,273,849 shares (+404.1%) to their portfolio in Q1 2025, for an estimated $9,553,867
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BIOCRYST PHARMACEUTICALS Government Contracts
We have seen $15,386,878 of award payments to $BCRX over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PERAMIVIR (RAPIVAB 200MG/20ML (10MG/ML INJ SOLN)): $13,877,673
- BULK ORLADEYO PHARMACEUTICAL: $394,853
- BULK ORDER ORLADEYO FOR VETERAN CARE.: $382,300
- BEROTRALSTAT HCL 150MG CAP,ORAL TRADE NAME: ORLADEYO 150MG CAP: $379,348
- BEROTRALSTAT HCL 150MG CAP,ORAL (ORLADEYO).: $350,531
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
BIOCRYST PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $BCRX in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 07/01/2025
- RBC Capital issued a "Outperform" rating on 06/30/2025
- Wedbush issued a "Outperform" rating on 06/30/2025
- Needham issued a "Buy" rating on 06/27/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/06/2025
- JP Morgan issued a "Overweight" rating on 05/06/2025
- Cantor Fitzgerald issued a "Overweight" rating on 04/29/2025
To track analyst ratings and price targets for BIOCRYST PHARMACEUTICALS, check out Quiver Quantitative's $BCRX forecast page.
BIOCRYST PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $BCRX recently. We have seen 9 analysts offer price targets for $BCRX in the last 6 months, with a median target of $17.0.
Here are some recent targets:
- Tazeen Ahmad from B of A Securities set a target price of $15.0 on 07/01/2025
- Brian Abrahams from RBC Capital set a target price of $13.0 on 06/30/2025
- Laura Chico from Wedbush set a target price of $18.0 on 06/30/2025
- Serge Belanger from Needham set a target price of $17.0 on 06/27/2025
- Gena Wang from Barclays set a target price of $11.0 on 05/07/2025
- Andrew Fein from HC Wainwright & Co. set a target price of $30.0 on 05/06/2025
- Jessica Fye from JP Morgan set a target price of $13.0 on 05/06/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
